Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Jun;72(6):499-506.
doi: 10.1136/jech-2017-210338. Epub 2018 Feb 2.

Associations of Dyslipidaemia and Lipid-Lowering Treatment With Risk of Postoperative Cognitive Dysfunction: A Systematic Review and Meta-Analysis

Affiliations
Meta-Analysis

Associations of Dyslipidaemia and Lipid-Lowering Treatment With Risk of Postoperative Cognitive Dysfunction: A Systematic Review and Meta-Analysis

Insa Feinkohl et al. J Epidemiol Community Health. .

Abstract

Background: Lipid imbalance is linked to age-related cognitive impairment, but its role in postoperative cognitive dysfunction (POCD) is unknown. Here, we present a systematic review and meta-analysis on dyslipidaemia, lipid-lowering treatment and POCD risk.

Methods: PubMed, Ovid SP and Cochrane databases were searched for longitudinal studies that reported on associations of any measure of dyslipidaemia and/or lipid-lowering treatment with POCD as relative risks (RRs) or ORs. Fixed-effects inverse variance models were used to combine effects.

Results: Of 205 articles identified in the search, 17 studies on 2725 patients (grand mean age 67 years; mean age range 61-71 years) with follow-up periods of 1 day to 4 years (median 7 days; IQR 1-68 days) were included. Studies focused almost exclusively on hypercholesterolaemia as a measure of dyslipidaemia and on statins as lipid-lowering treatment. Across 12 studies on hypercholesterolaemia, we found no association with POCD risk (RR 0.93; 95% CI 0.80 to 1.08; P=0.34). Statin use before surgery was associated with a reduced POCD risk across eight studies (RR 0.81; 95% CI 0.67 to 0.98; P=0.03), but data on treatment duration were lacking.

Conclusion: Statin users appear to be at reduced risk of POCD although hypercholesterolaemia per se may not be associated with POCD risk. Trial studies are needed to evaluate the usefulness of statins in POCD prevention.

Keywords: cognition; lipids; meta analysis.

Conflict of interest statement

Competing interests: GW is coordinator of the BioCog consortium and CEO of Pharmaimage Biomarker Solutions GmbH (http://www.pi-pharmaimage.com). The company is one of the partners of the BioCog consortium. TP is workpackage leader (WP3) of BioCog.

Similar articles

See all similar articles

Cited by 3 articles

Publication types

MeSH terms

Substances

LinkOut - more resources

Feedback